Cytolysis in the practice of a primary care physician
https://doi.org/10.15829/3034-4123-2025-41
EDN: UBVBOQ
Abstract
Aim. To study the main causes of increased aminotransferase levels in the practice of a primary care physician.
Material and methods. The scientific literature was analyzed using the PubMed and eLIBRARY.RU databases by following keywords: cytolysis syndrome, aminotransferases, hypertransferasemia, increased alanine aminotransferase, increased aspartate aminotransferase. Based on the literature search, data on the most common cytolysis causes in clinical practice were analyzed and systematized, and a step-by-step algorithm for diagnostic search was presented.
Results. In clinical practice, cytolysis syndrome can be detected both among patients with existing complaints from the digestive system at the time of examination, and in asymptomatic patients (random diagnostic finding during a preventive medical examination).
Conclusion. To determine the strategy of managing a patient with cytolysis, the etiological factor should be clearly and accurately verified, which sometimes requires a long time and routine expensive research methods.
About the Authors
M. A. Livzan
Omsk State Medical University
Russian Federation
Russian Federation
Omsk
O. V. Gaus
Omsk State Medical University
Russian Federation
Russian Federation
Omsk
M. A. Lisovsky
Omsk State Medical University
Russian Federation
Russian Federation
Omsk
References
1. Hall P, Cash J. What is the real function of the liver ‘function’ tests? Ulster Med J. 2012;81(1):30-6.
2. Thachil J. Relevance of clotting tests in liver disease. Postgrad Med J. 2008;84(990):177-81. doi:10.1136/pgmj.2007.066415.
3. Cuperus FJC, Drenth JPH, Tjwa ET. Mistakes in liver function test abnormalities and how to avoid them. UEG Education. 2017;17:1-5.
4. Livzan MA, Gaus OV, Lisovskij MA. Differential Diagnosis of Liver Pathology in Cytolysis Syndrome: Clinical Case Analysis. Effective pharmacotherapy. 2023;19(35):22-9. (In Russ.) doi:10.33978/2307-3586-2023-19-35-22-29.
5. Radcke S, Dillon JF, Murray AL. A systematic review of the prevalence of mildly abnormal liver function tests and associated health outcomes. Eur J Gastroenterol Hepatol. 2015;27(1):1-7. doi:10.1097/MEG.0000000000000233.
6. Kamiike W, Fujikawa M, Koseki M, et al. Different patterns of leakage of cytosolic and mitochondrial enzymes. Clin Chim Acta. 1989;185(3):265-70. doi:10.1016/0009-8981(89)90216-7.
7. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol. 2006;101(1):76-82. doi:10.1111/j.1572-0241.2005.00341.x.
8. Aulbach AD, Amuzie CJ. Chapter 17 — Biomarkers in Nonclinical Drug Development. In: Faqi AS. A Comprehensive Guide to Toxicology in Nonclinical Drug Development (Second Edition). Cambridge (MA): Academic Press. 2017; 447-71.
9. Sparling DW. Chapter 3 — Bioindicators of Contaminant Exposure. In: Sparling DW. Ecotoxicology Essentials. San Diego: Academic Press. 2016;45-66.
10. Reichling JJ, Kaplan MM. Clinical use of serum enzymes in liver disease. Dig Dis Sci. 1988;33(12):1601-14. doi:10.1007/BF01535953.
11. Chuang CC, Chen WC, Lee SY, et al. Kaohsiung J Med Sci. 1996;12(9):544-8.
12. Pettersson J, Hindorf U, Persson P, et al. Muscular exercise can cause highly pathological liver function tests in healthy men. Br J Clin Pharmacol. 2008;65(2):253-9. doi:10.1111/j.1365-2125.2007.03001.x.
13. Newsome PN, Cramb R, Davison SM, et al. Guidelines on the management of abnormal liver blood tests. Gut. 2018;67(1):6-19. doi:10.1136/gutjnl-2017-314924.
14. Kalas MA, Chavez L, Leon M, et al. Abnormal liver enzymes: A review for clinicians. World J Hepatol. 2021;13(11):1688-98. doi:10.4254/wjh.v13.i11.1688.
15. Sullivan MK, Daher HB, Rockey DC. Normal or near normal aminotransferase levels in patients with alcoholic cirrhosis. Am J Med Sci. 2022;363(6):484-9. doi:10.1016/j.amjms.2021.09.012.
16. Ivashkin VT, Maevskaya MV, Zharkova MS, et al. Clinical Recommendations of the Russian Scientific Liver Society and Russian Gastroenterological Association on Diagnosis and Treatment of Liver Fibrosis, Cirrhosis and Their Complications. Rus J Gastroenterol Hepatol Coloproctol. 2021;31(6):56-102. (In Russ.) doi:10.22416/1382-4376-2021-31-6-56-102.
17. Al-Chalabi T, Underhill JA, Portmann BC, et al. Effects of serum aspartate aminotransferase levels in patients with autoimmune hepatitis influence disease course and outcome. Clin Gastroenterol Hepatol. 2008;6(12):1389-95. doi:10.1016/j.cgh.2008.08.018.
18. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005;172(3):367-79. doi:10.1503/cmaj.1040752.
19. Ivashkin VT, Maevskaya MV, Pavlov ChS, et al. Management of adult patients with alcoholic liver disease: clinical guidelines of the Russian Scientific Liver Society. Rus J Gastroenterol Hepatol Coloproctol. 2017;27(6):20-40. (In Russ.) doi:10.22416/1382-4376-2017-27-6-20-40.
20. Setshedi M, Wands JR, Monte SM. Acetaldehyde adducts in alcoholic liver disease. Oxid Med Cell Longev. 2010;3(3):178-85. doi:10.4161/oxim.3.3.12288.
21. Dunn W, Shah VH. Pathogenesis of Alcoholic Liver Disease. Clin Liver Dis. 2016;20(3):445-56. doi:10.1016/j.cld.2016.02.004.
22. Haber MM, West AB, Haber AD, et al. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol. 1995;90(8):1250-7.
23. Bacon BR, Farahvash MJ, Janney CG, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107(4):1103-9. doi:10.1016/0016-5085(94)90235-6.
24. Dunn W, Zeng Z, O’Neil M, et al. The interaction of rs738409, obesity, and alcohol: a population-based autopsy study. Am J Gastroenterol. 2012;107(11): 1668-74. doi:10.1038/ajg.2012.285.
25. Bueverov AO. Drug-induced liver damage. RMJ. 2012;3:107. (In Russ.)
26. Real M, Barnhill MS, Higley C, et al. Drug-Induced Liver Injury: Highlights of the Recent Literature. Drug Saf. 2019;42(3):365-87. doi:10.1007/s40264-018-0743-2.
27. Njoku DB. Drug-induced hepatotoxicity: metabolic, genetic and immunological basis. Int J Mol Sci. 2014;15(4):6990-7003. doi:10.3390/ijms15046990.
28. Bueverov AO. Basics of hepatology. M.: Publishing house "ABV-press". 2022; 408 p. (In Russ.) ISBN: 978-5-6046462-5-0.
29. Tujios SR, Lee WM. Acute liver failure induced by idiosyncratic reaction to drugs: Challenges in diagnosis and therapy. Liver Int. 2018;38(1):6-14. doi:10.1111/liv.13535.
30. Ezhov MV, Kukharchuk VV, Sergienko IV, et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.) doi:10.15829/1560-4071-2023-5471.
31. Lin E, Adams PC. Biochemical liver profile in hemochromatosis. A survey of 100 patients. J Clin Gastroenterol. 1991;13(3):316-20. doi:10.1097/00004836-199106000-00013.
32. European Association for the Study of the Liver. Electronic address: easloffice@ easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines on haemochromatosis. J Hepatol. 2023;79(5):1341. doi:10.1016/j.jhep.2023.09.002.
33. Brewer GJ. Practical recommendations and new therapies for Wilson’s disease. Drugs. 1995;50(2):240-9. doi:10.2165/00003495-199550020-00004.
34. Ryan A, Nevitt SJ, Tuohy O, et al. Biomarkers for diagnosis of Wilson’s disease. Cochrane Database Syst Rev. 2019(11):CD012267. doi:10.1002/14651858.CD012267.pub2.
35. Salman HM, Amin M, Syed J, et al. Biochemical testing for the diagnosis of Wilson’s disease: A systematic review. J Clin Lab Anal. 2022;36(2):e24191. doi:10.1002/jcla.24191.
36. Xu R, Jiang YF, Zhang YH, et al. The optimal threshold of serum ceruloplasmin in the diagnosis of Wilson’s disease: A large hospital-based study. PLoS One. 2018;13(1):e0190887. doi:10.1371/journal.pone.0190887.
37. Ranes J, Stoller JK. A review of alpha-1 antitrypsin deficiency. Semin Respir Crit Care Med. 2005;26(2):154-66. doi:10.1055/s-2005-869536.
38. Lomas DA, Evans DL, Finch JT, et al. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature. 1992;357(6379):605-7. doi:10.1038/357605a0.
39. Bardella MT, Fraquelli M, Quatrini M, et al. Prevalence of hypertransaminasemia in adult celiac patients and effect of gluten-free diet. Hepatology. 1995;22(3):833-6.
40. Bardella MT, Vecchi M, Conte D, et al. Chronic unexplained hypertransaminasemia may be caused by occult celiac disease. Hepatology. 1999;29(3):654-7. doi:10.1002/hep.510290318.
41. Ivashkin VT, Maevskaya MV, Zharkova MS, et al. Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. Rus J Gastroenterol Hepatol Coloproctol. 2022;32(4):104-40. (In Russ.) doi:10.22416/1382-4376-2022-32-4-104-140.
42. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57. doi:10.1002/hep.29367.
43. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunctionassociated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-9. doi:10.1016/j.jhep.2020.03.039.
44. Rinella ME, Lazarus JV, Ratziu V. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-86. doi:10.1097/HEP.0000000000000520.
45. Drapkina OM, Martynov AI, Arutyunov GP, et al. Resolution of the Expert Forum "New therapeutic horizons for NAFLD". Ther. Arch. 2024;96(2):186-93. (In Russ.) doi:10.26442/00403660.2024.02.202648.
46. Zhang Y, Sheng C, Wang D, et al. High-normal liver enzyme levels in early pregnancy predispose the risk of gestational hypertension and preeclampsia: A prospective cohort study. Front Cardiovasc Med. 2022;9:963957. doi:10.3389/fcvm.2022.963957.
47. Leng J, Zhang C, Wang P, et al. Plasma Levels of Alanine Aminotransferase in the First Trimester Identify High Risk Chinese Women for Gestational Diabetes. Sci Rep. 2016;6:27291. doi:10.1038/srep27291.
What is already known about the subject?
- Cytolysis is a common diagnostic finding in the clinical practice of a physician. The main task for a doctor is to determine the origin of increase transaminase levels, establish the scope of additional examination and prescribe adequate treatment.
What might this study add?
- The most common causes of cytolysis, including those of non-hepatic origin, are analyzed.
- The diagnostic minimum for differential diagnosis of liver diseases accompanied by an aminotransferase increase in the peripheral blood has been determined.
Review
For citations:
Livzan MA, Gaus OV, Lisovsky MA. Cytolysis in the practice of a primary care physician. Primary Health Care (Russian Federation). 2025;2(1):41-52. (In Russ.) https://doi.org/10.15829/3034-4123-2025-41. EDN: UBVBOQ
Views:
416
Email this article 